Parabilis Medicines
PrivateLast Round
Series F
1/8/2026
Total Funding Raised
$801M
Company Overview
Parabilis Medicines, formerly known as FogPharma, is a privately held, clinical-stage biopharmaceutical company focused on developing a new class of cancer treatments. The company's proprietary Helicon™ discovery platform engineers precisely-tuned, stabilized helical peptide therapeutics designed to target and unlock a wide range of traditionally undruggable protein-protein interactions that drive cancer. Its lead candidate, FOG-001, is a first-in-class inhibitor of the β-catenin:TCF interaction, a known driver in colorectal and other cancers, and is currently in Phase 1/2 clinical trials. The company leverages artificial intelligence and advanced data science in its discovery and development processes. In early 2024, the company secured $145 million in a Series E financing round to advance its clinical programs and platform.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Parabilis Medicines Comps
Public and private peers based on sector, stage, and business model.
Parabilis Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series F | 1/8/2026 | ||||
| Series E | 3/1/2024 | ||||
| Series D | 11/21/2022 | ||||
| Series C | 3/1/2021 | ||||
| Series B | 5/16/2018 |
Key People
Founding team and executive leadership
Parabilis Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series F |
| Janus Henderson Group | Series F |
| Horizons Ventures | Series B |
| Boyu Capital | Series B |
| RA Capital Management | Series E, Series F |
| Farallon Capital Management | Series F, Series C, Series E, Series D |
| Sixty Degree Capital | Series F, Series E |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 14, 2026
Konstantinos Kotarakos joins as Senior Vice President of Finance and Business Operations.
- Apr 14, 2026
Senior Vice President of Finance and Business Operations departs.
Parabilis Medicines Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Parabilis Medicines's valuation, stock price, and market status.
